How has Edgewise Therapeutics, Inc.'s operating lease liabilities changed year-over-year?

Edgewise Therapeutics, Inc.'s operating lease liabilities decreased by 9.5% year-over-year, from -$179K to -$196K.

Edgewise Therapeutics, Inc. EWTX Operating lease liabilities

Catalyst PharmaceuticalCPRX

——

Viking TherapeuticsVKTX

——

Scholar RockSRRK

——

ModernaMRNA

——

Operating income-$54.1M-17.7%

Net income-$49.0M-20.1%

EPS (diluted)-$0.46-7.0%

Cash & equivalents$33.2M-33.5%

Total debt$3.8M-16.8%

Total equity$493.2M+14.8%

Total assets$518.5M+14.1%

Operating cash flow-$42.5M-12.4%

CapEx$260.0K+491%

Free cash flow-$42.8M-12.9%

Market cap$4.18B+61.3%

Return on equity-38.1%+13.4pp

Debt / equity0×0.0×

Current ratio22.6×+1.6×

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Edgewise Therapeutics, Inc.'s operating lease liabilities?: Edgewise Therapeutics, Inc. (EWTX) reported operating lease liabilities of -$196K in Q1 2026.
How has Edgewise Therapeutics, Inc.'s operating lease liabilities changed year-over-year?: Edgewise Therapeutics, Inc.'s operating lease liabilities decreased by 9.5% year-over-year, from -$179K to -$196K.